Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 2 of 15

 
 

Smith & Nephew (NYSE:SNN)

Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
N/A

About Smith & Nephew

Smith & Nephew logoSmith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/24/2024Deutsche Bank AktiengesellschaftInitiated CoverageBuy
6/5/2024UBS GroupUpgradeNeutral ➝ Buy
11/28/2023BarclaysUpgradeUnderweight ➝ Equal Weight
11/3/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
10/31/2023HSBCUpgradeHold ➝ Buy
10/13/2023Stifel NicolausInitiated CoverageHold
8/8/2023UBS GroupUpgradeSell ➝ Neutral
4/27/2023HSBCDowngradeBuy ➝ Hold
4/11/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/29/2023BarclaysDowngradeOverweight ➝ Underweight
 

Act by Friday, August 16th, to collect this 22% dividend (Ad)

Let's do a little math here... To double your money at a 3% rate of return, you would need around 23 years. But at a 22% rate, you could double in less than 4 years! That's why I'm so excited to tell you about my #1 ETF for monthly income. With massive payouts of 22%, this ETF outperforms the average 3% yields from Dividends Aristocrats any time of the year. And a 22% dividend isn't the only thing unique about this story...

The ETF pays you every 30 days just to hold it.